Frizzled7 Antibody-Functionalized Nanoshells Enable Multivalent Binding for Wnt Signaling Inhibition in Triple Negative Breast Cancer Cells

Overview

Journal Small

Date 2017 May 26

PMID 28544579

Citations 34

Authors

Rachel S Riley

Emily S Day

Affiliations

Soon will be listed here.

Abstract

Antibodies that antagonize cell signaling pathways specific to their targeted receptor are invaluable tools to study and treat malignancies, but their utility is limited by high production costs and treatment dosages. Researchers have shown that antibodies conjugated to nanoparticles display increased affinity for their target relative to freely delivered antibodies due to multivalency, and this study investigates how this multivalency can enable antibody-nanoparticle conjugates to inhibit oncogenic cell signaling more effectively than freely delivered antibodies. This effect was evaluated using triple negative breast cancer (TNBC) cells that are characterized by hyperactive Wnt signaling mediated through overexpressed Frizzled7 (FZD7) transmembrane receptors. Through analysis of the expression of β-catenin and Axin2, two downstream targets in the Wnt pathway, the results demonstrate that FZD7 antibody-nanoshell conjugates (FZD7-NS) are drastically more effective at inhibiting Wnt signaling in TNBC cells than freely delivered FZD7 antibodies. Additionally, cells treated with FZD7-NS, but not cells treated with freely delivered FZD7 antibodies, have decreased viability, indicating the therapeutic potential of this technology. The results demonstrate that antibody-functionalized nanoparticles can exploit multivalency for improved signal cascade interference over free antibodies, and this may ultimately permit lower antibody dosages to be administered to study signaling pathways or to manage diseases.

Citing Articles

Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis.

Wang C, Wu L, Li X, Mao S, Wang Z, Xie H J Immunother Cancer. 2025; 13(2).

PMID: 40021214 PMC: 11873350. DOI: 10.1136/jitc-2024-009621.

Antibody/siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem-Like Behavior in Triple-Negative Breast Cancer Cells.

Hoover E, Day E J Biomed Mater Res A. 2025; 113(1):e37867.

PMID: 39760151 PMC: 11800355. DOI: 10.1002/jbm.a.37867.

Conjugation of Antibodies and siRNA Duplexes to Polymer Nanoparticles via Maleimide-Thiol Chemistry.

Hoover E, Roy Chowdhury C, Ruggiero O, Day E ACS Omega. 2024; 9(48):47637-47646.

PMID: 39651074 PMC: 11618400. DOI: 10.1021/acsomega.4c07025.

Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple-Negative Breast Cancer.

Dang M, Suri S, Li K, Casas C, Stigliano G, Riley R Adv Ther (Weinh). 2024; 7(6).

PMID: 39006318 PMC: 11238604. DOI: 10.1002/adtp.202300426.

Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers.

Liu H, Sun X, Xiu S, Zhang X, Wang Z, Gu Y Acta Pharmacol Sin. 2024; 45(8):1556-1570.

PMID: 38632318 PMC: 11272778. DOI: 10.1038/s41401-024-01270-3.

References

Maubant S, Tesson B, Maire V, Ye M, Rigaill G, Gentien D . Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS One. 2015; 10(4):e0122333. PMC: 4388387. DOI: 10.1371/journal.pone.0122333. View

Samaranayake H, Wirth T, Schenkwein D, Raty J, Yla-Herttuala S . Challenges in monoclonal antibody-based therapies. Ann Med. 2009; 41(5):322-31. DOI: 10.1080/07853890802698842. View

Segditsas S, Tomlinson I . Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 2006; 25(57):7531-7. DOI: 10.1038/sj.onc.1210059. View

Lee H, Dam D, Ha J, Yue J, Odom T . Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs. ACS Nano. 2015; 9(10):9859-67. PMC: 5279887. DOI: 10.1021/acsnano.5b05138. View

de Puig H, Bosch I, Carre-Camps M, Hamad-Schifferli K . Effect of the Protein Corona on Antibody-Antigen Binding in Nanoparticle Sandwich Immunoassays. Bioconjug Chem. 2017; 28(1):230-238. PMC: 5245486. DOI: 10.1021/acs.bioconjchem.6b00523. View

Scott A, Allison J, Wolchok J . Monoclonal antibodies in cancer therapy. Cancer Immun. 2012; 12:14. PMC: 3380347. View

King T, Suto M, Li Y . The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem. 2011; 113(1):13-8. PMC: 10924801. DOI: 10.1002/jcb.23350. View

Li M, Wang J, Schwartz J, Gill-Sharp K, Stoica G, Wang L . In-vivo photoacoustic microscopy of nanoshell extravasation from solid tumor vasculature. J Biomed Opt. 2009; 14(1):010507. PMC: 6988903. DOI: 10.1117/1.3081556. View

Weissleder R, Kelly K, Sun E, Shtatland T, Josephson L . Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005; 23(11):1418-23. DOI: 10.1038/nbt1159. View

10.

Sliwkowski M, Mellman I . Antibody therapeutics in cancer. Science. 2013; 341(6151):1192-8. DOI: 10.1126/science.1241145. View

11.

Griffiths C, Olin J . Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract. 2012; 25(3):319-23. DOI: 10.1177/0897190012442062. View

12.

Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035):843-50. DOI: 10.1038/nature03319. View

13.

King T, Zhang W, Suto M, Li Y . Frizzled7 as an emerging target for cancer therapy. Cell Signal. 2011; 24(4):846-51. PMC: 3268941. DOI: 10.1016/j.cellsig.2011.12.009. View

14.

Carpin L, Bickford L, Agollah G, Yu T, Schiff R, Li Y . Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat. 2010; 125(1):27-34. DOI: 10.1007/s10549-010-0811-5. View

15.

Day E, Zhang L, Thompson P, Zawaski J, Kaffes C, Gaber M . Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine (Lond). 2012; 7(8):1133-48. PMC: 5375028. DOI: 10.2217/nnm.11.189. View

16.

Park J, Hong K, Kirpotin D, Colbern G, Shalaby R, Baselga J . Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002; 8(4):1172-81. View

17.

Allen T . Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2(10):750-63. DOI: 10.1038/nrc903. View

18.

Loo C, Hirsch L, Lee M, Chang E, West J, Halas N . Gold nanoshell bioconjugates for molecular imaging in living cells. Opt Lett. 2005; 30(9):1012-4. DOI: 10.1364/ol.30.001012. View

19.

Jensen S, Day E, Ko C, Hurley L, Luciano J, Kouri F . Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013; 5(209):209ra152. PMC: 4017940. DOI: 10.1126/scitranslmed.3006839. View

20.

Angers S, Moon R . Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009; 10(7):468-77. DOI: 10.1038/nrm2717. View